Organon & Co.

OGN

Healthcare Drug Manufacturers General

Organon & Co.’s revenue for fiscal 2025 (year ended December 2025) was $6.2 billion, down 2.92% from fiscal 2024.

Revenue
−1.75%
EPS
+1.64%
Free cash flow
+118.8%
Total debt
−3.10%

Quarter to September 2026, against a year earlier

13.87 0.08 +0.58%
Market cap
$3.6B
P/E
17.3×
Fwd P/E
6.2×
Dividend yield
0.58%
F-score
5/9
ROIC
6.26%
Net debt / EBITDA
5.6×
Dividend safety
45/100
Dec '17 Dec '18 Dec '19 Dec '20 Dec '21 Dec '22 Dec '23 Dec '24 Dec '25
Piotroski F-Score
— — — — 4 5 4 5 5
P/E ratio
4.54 4.54 4.54 4.54 5.71 7.80 3.66 4.45 9.96
Altman Z-Score
— — — — 1.52 1.51 1.26 1.27 1.09
P/S ratio
1.35 1.35 1.35 1.35 1.22 1.16 0.60 0.60 0.30
Altman Z″-Score (non-manufacturers)
— — — — 1.41 1.64 1.68 1.81 1.78
P/FCF ratio
3.39 3.39 3.39 3.39 3.91 13.09 8.29 5.78 4.48
Beneish M-Score
— — — (2.93) (3.56) (2.40) (2.21) (2.62) (2.68)
P/Operating CF
6.48 6.48 6.48 6.48 164.26 26.71 9.46 9.83 13.20
Dividend Safety Score
— — — — — — — — 45
P/B ratio
1.79 1.79 1.79 1.79 0.00 0.00 0.00 8.13 2.47
EV/Sales
1.49 1.49 1.49 1.49 2.56 2.48 1.89 1.88 1.60
EV/EBITDA
3.75 3.75 3.75 3.75 8.38 8.61 7.92 7.24 6.92
EV/FCF
3.76 3.76 3.76 3.76 8.16 28.15 26.10 18.16 23.93
Current Ratio
— 2.40 2.95 1.33 1.45 1.56 1.54 1.60 1.82
Net Debt/EBITDA
0.00 (0.02) (0.05) 0.01 4.69 4.61 5.40 4.94 5.62
Debt/Equity
— 0.00 0.02 0.01 (6.06) (9.99) (125.14) 18.81 11.49
ROE
0.00% 32.18% 48.09% 34.50% 67.92% (76.42%) (212.68%) 429.85% 30.56%
ROA
0.00% 0.00% 61.02% 20.91% 13.00% 8.48% 8.89% 6.87% 1.44%
ROIC
— 0.00% 33.80% 31.74% 16.25% 13.41% 9.82% 9.90% 5.84%
Return on Tangible Assets
0.00% 76.35% 97.69% 115.02% 63.25% 37.63% 36.89% 30.88% 5.73%
Average Days of Receivables
0.00 59.92 69.18 58.00 80.02 87.20 101.64 77.41 78.16
Earnings Yield
22.04% 22.04% 22.04% 22.04% 17.50% 12.83% 27.33% 22.45% 10.04%
Free Cash Flow Yield
29.46% 29.46% 29.46% 29.46% 25.58% 7.64% 12.07% 17.29% 22.30%
Free Cash Flow per Share
13.51 14.30 11.57 8.02 7.03 2.15 2.14 2.58 1.60
Book value per Share
0.00 0.00 27.75 21.64 (5.95) (3.51) (0.27) 1.84 2.90
Free Cash Flow
3,419.00 3,618.00 2,932.00 2,034.00 1,783.00 545.00 547.00 663.00 415.00
EV/EBIT
4.01 4.01 4.01 4.01 9.00 9.77 9.40 8.76 12.05
Other line items

Show all line items

Columns are period end dates · fundamentals updated 5 Nov 2026